BioSpace News Archive

Between 12 and 20 percent of Americans over age 60 have peripheral arterial disease.

The 2015 outbreak of the Zika virus in South America, Central America, and the United States galvanized countries to increase vector control measures to quickly reduce mosquito populations.

Stanford Children’s Health announced that it has achieved Magnet recognition as a reflection of its exemplary professional nursing practice, interprofessional teamwork and preeminent patient care.

Health systems must view their physician enterprise as a critical strategic business unit

Feinstein Institutes for Medical Research Professor David Eidelberg, MD, has received a five-year, $2.9 million grant from the National Institutes of Health (NIH) to support his research in developing a way to delay or prevent negative effects of a common treatment in those with Parkinson’s disease.

NASA Johnson Space Center will provide its unique, advanced risk-management services as part of a Space Act Agreement with BiVACOR Inc., Houston, in the company’s efforts to improve the robustness and reliability of its Total Artificial Heart (TAH) system – an implantable rotary bi-ventricular blood pump and associated external electronics.

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two investor conferences in October.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, which is being held next week in New York. Exelixis’ presentation has been scheduled for Wednesday, October 2, 2019 at 8:55 AM EDT / 5:55 AM PDT.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, and CARB-X, a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria, announced today that the T2Resistance™ Panel is the first diagnostic to graduate from CARB-X’s portfolio.

The surgery was performed, implanting the H3, three-component, non-cemented, non-constrained total ankle replacement system, at Lakewood Ranch Medical Center in Sarasota, Florida by Dr. James Cottom of Florida Orthopedic Foot and Ankle Center.